keyword
MENU ▼
Read by QxMD icon Read
search

the lancet

keyword
https://www.readbyqxmd.com/read/29221458/a-cohort-examination-to-establish-reporting-of-the-remit-and-function-of-trial-steering-committees-in-randomised-controlled-trials
#1
Elizabeth J Conroy, Barbara Arch, Nicola L Harman, J Athene Lane, Steff C Lewis, John Norrie, Matthew R Sydes, Carrol Gamble
BACKGROUND: The DAMOCLES project established a widely used Data Monitoring Committee (DMC) Charter for randomised controlled trials (RCTs). Typically, within the UK, the DMC is advisory and recommends to another executive body; the Trial Steering Committee (TSC). Despite the executive role of the TSC, the CONSORT Statement does not explicitly require reporting of TSC activity, although is included as an example of good reporting. A lack of guidance on TSC reporting can impact transparency of trial oversight, ultimately leading to a misunderstanding regarding role and, subsequently, further variation in practice...
December 8, 2017: Trials
https://www.readbyqxmd.com/read/29217150/breaking-the-ice
#2
EDITORIAL
The Lancet Psychiatry
No abstract text is available yet for this article.
December 4, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/29213225/role-of-blue-dye-for-sentinel-lymph-node-detection-in-early-endometrial-cancer
#3
Stefano Restaino, Carlo Ronsini, Angelo Finelli, Emanuele Perrone, Giovanni Scambia, Francesco Fanfani
Background: Sentinel Lymphonode analysis has become a barely new and innovative way to treat early stages of endometrial cancer (Ballester et al., Lancet Oncol 469-476, 2011; Buda et al., Ann Surg Oncol 2975-81, 2016). Indocyanine green cervical injection is considered gold standard for mapping nodes' drainage. Blue dye is used as a valid alternative in many centers, due to the lower cost of execution. The objective of this video is to prove that methylene blue dye's cervical injection is a valid and "low-cost" method to obtain mapping of lymphatic drainage in patient with early endometrial cancer...
2017: Gynecological Surgery
https://www.readbyqxmd.com/read/29208427/clinical-decision-making-more-than-just-an-algorithm
#4
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
December 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29208398/future-cancer-research-priorities-in-the-usa-a-lancet-oncology-commission
#5
REVIEW
Elizabeth M Jaffee, Chi Van Dang, David B Agus, Brian M Alexander, Kenneth C Anderson, Alan Ashworth, Anna D Barker, Roshan Bastani, Sangeeta Bhatia, Jeffrey A Bluestone, Otis Brawley, Atul J Butte, Daniel G Coit, Nancy E Davidson, Mark Davis, Ronald A DePinho, Robert B Diasio, Giulio Draetta, A Lindsay Frazier, Andrew Futreal, Sam S Gambhir, Patricia A Ganz, Levi Garraway, Stanton Gerson, Sumit Gupta, James Heath, Ruth I Hoffman, Cliff Hudis, Chanita Hughes-Halbert, Ramy Ibrahim, Hossein Jadvar, Brian Kavanagh, Rick Kittles, Quynh-Thu Le, Scott M Lippman, David Mankoff, Elaine R Mardis, Deborah K Mayer, Kelly McMasters, Neal J Meropol, Beverly Mitchell, Peter Naredi, Dean Ornish, Timothy M Pawlik, Jeffrey Peppercorn, Martin G Pomper, Derek Raghavan, Christine Ritchie, Sally W Schwarz, Richard Sullivan, Richard Wahl, Jedd D Wolchok, Sandra L Wong, Alfred Yung
We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment...
November 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29208375/cancer-control-in-africa-infrastructure-not-philanthropy
#6
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
November 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29208295/far-from-universal-access-to-electricity
#7
EDITORIAL
The Lancet
No abstract text is available yet for this article.
December 2, 2017: Lancet
https://www.readbyqxmd.com/read/29208294/hearing-loss-time-for-sound-action
#8
EDITORIAL
The Lancet
No abstract text is available yet for this article.
December 2, 2017: Lancet
https://www.readbyqxmd.com/read/29198562/disease-burden-and-costs-from-excess-alcohol-consumption-obesity-and-viral-hepatitis-fourth-report-of-the-lancet-standing-commission-on-liver-disease-in-the-uk
#9
REVIEW
Roger Williams, Graeme Alexander, Iain Armstrong, Alastair Baker, Neeraj Bhala, Ginny Camps-Walsh, Matthew E Cramp, Simon de Lusignan, Natalie Day, Anil Dhawan, John Dillon, Colin Drummond, Jessica Dyson, Graham Foster, Ian Gilmore, Mark Hudson, Deirdre Kelly, Andrew Langford, Neil McDougall, Petra Meier, Kieran Moriarty, Philip Newsome, John O'Grady, Rachel Pryke, Liz Rolfe, Peter Rice, Harry Rutter, Nick Sheron, Alison Taylor, Jeremy Thompson, Douglas Thorburn, Julia Verne, John Wass, Andrew Yeoman
This report contains new and follow-up metric data relating to the eight main recommendations of the Lancet Standing Commission on Liver Disease in the UK, which aim to reduce the unacceptable harmful consequences of excess alcohol consumption, obesity, and viral hepatitis. For alcohol, we provide data on alcohol dependence, damage to families, and the documented increase in alcohol consumption since removal of the above-inflation alcohol duty escalator. Alcoholic liver disease will shortly overtake ischaemic heart disease with regard to years of working life lost...
November 28, 2017: Lancet
https://www.readbyqxmd.com/read/29196412/a-phase-1-trial-of-vadastuximab-talirine-as-monotherapy-in-patients-with-cd33-positive-acute-myeloid-leukemia-aml
#10
Eytan M Stein, Roland B Walter, Harry P Erba, Amir T Fathi, Anjali S Advani, Jeffrey E Lancet, Farhad Ravandi, Tibor Kovacsovics, Daniel J DeAngelo, Dale Bixby, Stefan Faderl, Anand P Jillella, Phoenix Ho, Megan M O'Meara, Baiteng Zhao, Charles Biddle-Snead, Anthony S Stein
Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed in the majority of acute myeloid leukemia (AML) patients. This phase 1 study (clinicaltrials.gov NCT01902329) evaluated the safety, pharmacokinetics, and preliminary activity of vadastuximab talirine and determined the recommended monotherapy dose in patients with relapsed or refractory AML. Additional expansion cohorts tested vadastuximab talirine in specific subpopulations of relapsed AML, and in a cohort of older, treatment-naïve patients...
December 1, 2017: Blood
https://www.readbyqxmd.com/read/29195598/orphan-drug-approval-for-erdheim-chester-disease
#11
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
December 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29191412/next-year-in-the-lancet-hiv
#12
EDITORIAL
The Lancet Hiv
No abstract text is available yet for this article.
December 2017: Lancet HIV
https://www.readbyqxmd.com/read/29189896/between-a-rux-and-a-hard-place-evaluating-salvage-treatment-and-outcomes-in-myelofibrosis-after-ruxolitinib-discontinuation
#13
Andrew T Kuykendall, Savan Shah, Chetasi Talati, Najla Al Ali, Kendra Sweet, Eric Padron, David A Sallman, Jeffrey E Lancet, Alan F List, Kenneth S Zuckerman, Rami S Komrokji
Ruxolitinib is a JAK1/2 inhibitor that is effective in managing symptoms and splenomegaly related to myelofibrosis (MF). Unfortunately, many patients must discontinue ruxolitinib, at which time treatment options are not well defined. In this study, we investigated salvage treatment options and clinical outcomes among MF patients who received and discontinued ruxolitinib outside the context of a clinical trial. Among 145 patients who received ruxolitinib, 23 died while on treatment, 58 remained on treatment at time of analysis, leaving 64 people available for analysis...
November 30, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29185424/pledge-deaths-in-us-colleges
#14
EDITORIAL
The Lancet
No abstract text is available yet for this article.
November 25, 2017: Lancet
https://www.readbyqxmd.com/read/29185423/caring-for-migrant-health-care-workers
#15
EDITORIAL
The Lancet
No abstract text is available yet for this article.
November 25, 2017: Lancet
https://www.readbyqxmd.com/read/29179921/mental-health-law-revision-or-reformation
#16
EDITORIAL
The Lancet Psychiatry
No abstract text is available yet for this article.
December 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/29174127/heart-failure-in-an-ageing-population
#17
EDITORIAL
The Lancet
No abstract text is available yet for this article.
November 22, 2017: Lancet
https://www.readbyqxmd.com/read/29173874/climate-change-the-role-of-the-infectious-disease-community
#18
EDITORIAL
The Lancet Infectious Diseases
No abstract text is available yet for this article.
December 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29173499/good-value-care-when-less-is-more
#19
EDITORIAL
The Lancet Diabetes Endocrinology
No abstract text is available yet for this article.
December 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29172995/pd-l1-blockade-with-avelumab-a-new-paradigm-for-treating-merkel-cell-carcinoma
#20
Savannah Barkdull, Isaac Brownell
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer. Until recently, no durable treatment options were available for patients with advanced disease. As an immunogenic cancer, MCC was hypothesized to be a candidate for PD-L1/PD-1 targeted therapy. On March 23, 2017 the US Food and Drug Administration granted accelerated approval for avelumab, an anti-PD-L1 monoclonal antibody, for the treatment of metastatic MCC on the basis of the JAVELIN Merkel 200 trial. Here we examine the results and implications of this pivotal study, published in Lancet Oncology by Kaufman et al...
November 27, 2017: Cancer Biology & Therapy
keyword
keyword
52159
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"